Document is current
Any future updates will be listed below
-
Authors
Tuccinardi, Dario https://orcid.org/0000-0002-9139-7159
Masi, Davide
Watanabe, Mikiko
Zanghi Buffi, Valeria
De Domenico, Francesco
Berti, Sabrina
Cipriani, Valentina
Manco, Melania
Manfrini, Silvia
Pagotto, Uberto
-
Funding
Funding for this research was provided by:
EUROPEAN UNION (NextGenerationEU, under the Italian Ministry of University and Research (MUR) PRIN 2022 program, Mission 4, Component 1, CUP C53D23006490001.)
- License Information
-
More Information
Article History
Received: 9 August 2025
Accepted: 29 August 2025
First Online: 10 November 2025
Declarations
:
: The authors declare no conflicts of interest related to the content of this manuscript. UP is Editor in Chief of The Journal of Endocrinological Investigation. The manuscript will be handled by an independent editor. UP is a member of Advisory Boards of Novo Nordisk, Sciterion, Boehringer Ingelheim, Pfizer, Lilly Italia, Lilly Corporate and he received speaker fees from: Lilly Italia, Novo Nordisk, Astra-Zeneca, Bruno Farmaceutici, Rhythm Pharma, Merck, IQVIA; DT received funding for educational sessions from: Novo Nordisk, Eli Lilly, Boehringer-Ingelheim, Guidotti, Astra Zeneca, Sanofi and Bruno Farmaceutici; for institutional research grant support or funding for clinical trials from Novo Nordisk, Eli Lilly, Abbott, Boehringer-Ingelheim, Amgen, and Astra Zeneca; and Institutional Scientific Board and/or consulting from Eli Lilly, Astra Zeneca, and Novo Nordisk. MW received funding for educational sessions from: Novo Nordisk, Eli Lilly, Theras Lifetech and Bruno Farmaceutici; and Institutional Scientific Board and/or consulting from Eli Lilly, Theras Lifetech, and Novo Nordisk.
